Do not Disregard the Standardization of Vaccine Research

The Food and Drug Monitoring Agency (BPOM) confirmed that research for the Nusantara vaccine cannot continue onto its second phase as many aspects need to be corrected according to scientific principles.

KOMPAS/RUNIK SRI ASTUTI

Head of the Food and Drug Administration (BPOM) Penny K Lukito while checking the Sinovac Covid-19 vaccine storage facility at the Sidoarjo Health Office, East Java, Tuesday (23/2/2021).

BANDUNG, KOMPAS – Controversy regarding the development of the Nusantara vaccine must be resolved immediately so as not to hamper COVID-19 vaccine needs in the country. For optimal results, research standardization should not be ignored.

Food and Drug Monitoring Agency (BPOM) head Penny K. Lukito emphasized, while reviewing the development of the Merah Putih vaccine at Bio Farma, Bandung, West Java, Friday (16/4/2021), that vaccine development must adhere to the existing standards as it concerns human safety.